HI
NTLA icon

Harbour Investments’s Intellia Therapeutics NTLA Stock Holding History

Harbour Investments’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$94.2K Buy
7,349
+524
+8% +$6.67K ﹤0.01% 1982
2025
Q4 		$61.4K Buy
6,825
+269
+4% +$3.7K ﹤0.01% 1868
2025
Q3 		$113K Sell
6,556
-77
-1% -$948 ﹤0.01% 1527
2025
Q2 		$62.2K Buy
6,633
+1,419
+27% +$11.7K ﹤0.01% 1710
2025
Q1 		$37.1K Buy
5,214
+2,264
+77% +$22.9K ﹤0.01% 1919
2024
Q4 		$34.4K Buy
2,950
+784
+36% +$12.2K ﹤0.01% 1893
2024
Q3 		$44.5K Buy
2,166
+455
+27% +$10.5K ﹤0.01% 1725
2024
Q2 		$38.3K Buy
1,711
+86
+5% +$2.05K ﹤0.01% 1683
2024
Q1 		$44.7K Buy
1,625
+861
+113% +$23.9K ﹤0.01% 1575
2023
Q4 		$23.3K Buy
+764
New +$22K ﹤0.01% 1806
2021
Q4 		$5K Sell
43
-19
-31% -$2.38K ﹤0.01% 2183
2021
Q3 		$8K Buy
62
+9
+17% +$1.36K ﹤0.01% 2778
2021
Q2 		$9K Buy
53
+21
+66% +$1.64K ﹤0.01% 2801
2021
Q1 		$3K Buy
+32
New +$2.15K ﹤0.01% 3107

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Harbour Investments's NTLA Position: Q1 2026 in Review

Harbour Investments increased its Intellia Therapeutics (NTLA) stake by 7.7% in Q1 2026, buying an estimated $6.67K and bringing the position to 7,349 shares worth $94.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1982.

Harbour Investments first reported a position in NTLA in Q1 2021 and has held it in 14 quarters since. The position peaked at $113K in Q3 2025. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Harbour Investments held 7,349 shares of Intellia Therapeutics worth $94.2K as of Q1 2026.
  • Harbour Investments bought 524 Intellia Therapeutics shares in Q1 2026, an estimated $6.67K.
  • Intellia Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q1 2026, its #1982 holding.
  • Harbour Investments first reported a position in Intellia Therapeutics in Q1 2021 and has held it in 14 quarters since.
  • Harbour Investments's Intellia Therapeutics position peaked at $113K in Q3 2025.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.